![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://www.bmj.com/content/bmj/385/bmj-2023-078483/F2.large.jpg)
dpp4 vs sglt2 vs glp-1
Shipping Estimate
dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]
USD21.98
USD44.98
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/dpp4.png?w=600&tok=f9724b)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://www.researchgate.net/publication/326514429/figure/fig2/AS:871597430812676@1584816429921/Short-list-of-add-on-antihyperglycemic-agents-showing-CV-superiority-or-safety-CV.png)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=10155413610538341&get_thumbnail=1)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://figures.semanticscholar.org/c15f0327b75d4570d8ee6263ce3f83d7e6f770a3/2-Table1-1.png)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://figures.semanticscholar.org/c042cb1f8a5f66400663a1b3667fb43dca012b91/2-Table2-1.png)
